Serial 18F-Fluorodeoxyglucose Positron Emission Tomography to Assess the Efficacy of Infliximab in Steroid Refractory Cardiac Sarcoidosis

Louise E. Crowley; Ellen Jenkins; Akalanka Ranasinghe; Tamara Naneishvili; Mengshi Yuan; Khalid Hussain; Francisco Leyva-Leon; Anjali Crawshaw; William E. Moody

doi:10.1016/j.nuclcard.2025.102265

Serial ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography to Assess the Efficacy of Infliximab in Steroid Refractory Cardiac Sarcoidosis

Louise E. Crowley, Ellen Jenkins, Akalanka Ranasinghe, Tamara Naneishvili, Mengshi Yuan, Khalid Hussain, Francisco Leyva-Leon, Anjali Crawshaw, William E. Moody

Research output: Contribution to journal › Article › peer-review

Abstract

Graphical abstract (only): Legend: Graphical abstract summarizing the findings of this observational study, which through serial 18F-FDG-PET/CT imaging, supports the use of infliximab in the management of refractory cardiac sarcoidosis. CMA - cardiac metabolic activity, EF - ejection fraction, 18F-FDG-PET/CT - fluorodeoxyglucose-positron emission tomography/computed tomography, LV - left ventricular, MRI - magnetic resonance imaging, SUV - standardized uptake value.

Original language	English
Article number	102265
Journal	Journal of Nuclear Cardiology
Early online date	9 Jun 2025
DOIs	https://doi.org/10.1016/j.nuclcard.2025.102265
Publication status	E-pub ahead of print - 9 Jun 2025

Bibliographical note

Copyright © 2025 The Author(s). Published by Elsevier Inc. on behalf of American Society of Nuclear Cardiology. This work is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).

Access to Document

10.1016/j.nuclcard.2025.102265Licence: CC BY 4.0

1-s2.0-S1071358125001394-main
Copyright © 2025 The Author(s). Published by Elsevier Inc. on behalf of American Society of Nuclear Cardiology. This work is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).
Accepted author manuscript, 1.94 MBLicence: CC BY 4.0

Cite this

Crowley, L. E., Jenkins, E., Ranasinghe, A., Naneishvili, T., Yuan, M., Hussain, K., Leyva-Leon, F., Crawshaw, A., & Moody, W. E. (2025). Serial ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography to Assess the Efficacy of Infliximab in Steroid Refractory Cardiac Sarcoidosis. Journal of Nuclear Cardiology, Article 102265. Advance online publication. https://doi.org/10.1016/j.nuclcard.2025.102265

@article{bb4dd230adc74f098d5d9407f8debfe2,

title = "Serial 18F-Fluorodeoxyglucose Positron Emission Tomography to Assess the Efficacy of Infliximab in Steroid Refractory Cardiac Sarcoidosis",

abstract = "Graphical abstract (only): Legend: Graphical abstract summarizing the findings of this observational study, which through serial 18F-FDG-PET/CT imaging, supports the use of infliximab in the management of refractory cardiac sarcoidosis. CMA - cardiac metabolic activity, EF - ejection fraction, 18F-FDG-PET/CT - fluorodeoxyglucose-positron emission tomography/computed tomography, LV - left ventricular, MRI - magnetic resonance imaging, SUV - standardized uptake value.",

author = "Crowley, {Louise E.} and Ellen Jenkins and Akalanka Ranasinghe and Tamara Naneishvili and Mengshi Yuan and Khalid Hussain and Francisco Leyva-Leon and Anjali Crawshaw and Moody, {William E.}",

note = "Copyright {\textcopyright} 2025 The Author(s). Published by Elsevier Inc. on behalf of American Society of Nuclear Cardiology. This work is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).",

year = "2025",

month = jun,

day = "9",

doi = "10.1016/j.nuclcard.2025.102265",

language = "English",

}

TY - JOUR

T1 - Serial 18F-Fluorodeoxyglucose Positron Emission Tomography to Assess the Efficacy of Infliximab in Steroid Refractory Cardiac Sarcoidosis

AU - Crowley, Louise E.

AU - Jenkins, Ellen

AU - Ranasinghe, Akalanka

AU - Naneishvili, Tamara

AU - Yuan, Mengshi

AU - Hussain, Khalid

AU - Leyva-Leon, Francisco

AU - Crawshaw, Anjali

AU - Moody, William E.

N1 - Copyright © 2025 The Author(s). Published by Elsevier Inc. on behalf of American Society of Nuclear Cardiology. This work is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).

PY - 2025/6/9

Y1 - 2025/6/9

N2 - Graphical abstract (only): Legend: Graphical abstract summarizing the findings of this observational study, which through serial 18F-FDG-PET/CT imaging, supports the use of infliximab in the management of refractory cardiac sarcoidosis. CMA - cardiac metabolic activity, EF - ejection fraction, 18F-FDG-PET/CT - fluorodeoxyglucose-positron emission tomography/computed tomography, LV - left ventricular, MRI - magnetic resonance imaging, SUV - standardized uptake value.

AB - Graphical abstract (only): Legend: Graphical abstract summarizing the findings of this observational study, which through serial 18F-FDG-PET/CT imaging, supports the use of infliximab in the management of refractory cardiac sarcoidosis. CMA - cardiac metabolic activity, EF - ejection fraction, 18F-FDG-PET/CT - fluorodeoxyglucose-positron emission tomography/computed tomography, LV - left ventricular, MRI - magnetic resonance imaging, SUV - standardized uptake value.

UR - https://www.sciencedirect.com/science/article/pii/S1071358125001394

U2 - 10.1016/j.nuclcard.2025.102265

DO - 10.1016/j.nuclcard.2025.102265

M3 - Article

C2 - 40499889

SN - 1071-3581

JO - Journal of Nuclear Cardiology

JF - Journal of Nuclear Cardiology

M1 - 102265

ER -

Serial ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography to Assess the Efficacy of Infliximab in Steroid Refractory Cardiac Sarcoidosis

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this